Use of bone turnover markers in the management of osteoporosis

被引:69
作者
Jain, Sumeet [1 ]
Camacho, Pauline [1 ]
机构
[1] Loyola Univ Med Ctr, 2160 S 1st Ave, Maywood, IL 60153 USA
关键词
bone turnover markers; C-terminal telopeptide of type I collage; N-terminal propeptide of type I collagen; osteoporosis; REFERENCE INTERVALS; BIOCHEMICAL MARKERS; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; VERTEBRAL FRACTURE; GLUCOSE-TOLERANCE; MINERAL DENSITY; GLA-PROTEIN; FOLLOW-UP; RESORPTION;
D O I
10.1097/MED.0000000000000446
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Osteoporosis is a common public health problem that is often undertreated and underdiagnosed. The clinical management of osteoporosis is often reactionary to devastating fracture events. Bone turnover markers may improve the ease and rapidity at which osteoporosis is monitored and treated. Bone turnover markers are biochemical byproducts of bone formation or bone resorption. The clinical use of bone turnover markers is limited by significant preanalytical variability. Effective interpretation of bone turnover markers requires a detailed understanding of the variables that can affect their responses to osteoporosis treatment and monitoring. Recent findings Progress is continuously being made on the standardization of bone turnover markers. The literature on the response of bone turnover markers to unique clinical situations is expanding. Data for evidence-based reference intervals for bone turnover markers has increased. Variables that affect the appropriate timing of lab draws like diurnal variation, postprandial status, exercise and alcohol use have been described. Studies examining the expected response of bone turnover markers to treatments of osteoporosis and other medications that affect bone health continue to increase. Bone turnover markers have clinical utility in the comprehensive evaluation of osteoporosis. When interpreted with caution and with a good understanding of their natural variability, bone turnover markers provide information that supplements osteoporosis management and provides useful clinical information about conditions that alter bone turnover.
引用
收藏
页码:366 / 372
页数:7
相关论文
共 71 条
[1]   Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, DM ;
Garnero, P ;
Hochberg, M ;
Ott, S ;
Orloff, J ;
Thompson, DE ;
Ewing, SK ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (08) :1250-1258
[2]   Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy The FLEX Study [J].
Bauer, Douglas C. ;
Schwartz, Ann ;
Palermo, Lisa ;
Cauley, Jane ;
Hochberg, Marc ;
Santora, Art ;
Cummings, Steven R. ;
Black, Dennis M. .
JAMA INTERNAL MEDICINE, 2014, 174 (07) :1126-1134
[3]   Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin [J].
Bilezikian, John P. ;
Watts, Nelson B. ;
Usiskin, Keith ;
Polidori, David ;
Fung, Albert ;
Sullivan, Daniel ;
Rosenthal, Norm .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (01) :43-50
[4]   Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass [J].
Bone, Henry G. ;
Bolognese, Michael A. ;
Yuen, Chui Kin ;
Kendler, David L. ;
Miller, Paul D. ;
Yang, Yu-Ching ;
Grazette, Luanda ;
San Martin, Javier ;
Gallagher, J. Christopher .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2011, 96 (04) :972-980
[5]   Bone turnover markers in the management of postmenopausal osteoporosis [J].
Brown, Jacques P. ;
Albert, Caroline ;
Nassar, Bassam A. ;
Adachi, Jonathan D. ;
Cole, David ;
Davison, K. Shawn ;
Dooley, Kent C. ;
Don-Wauchope, Andrew ;
Douville, Pierre ;
Hanley, David A. ;
Jamal, Sophie A. ;
Josse, Robert ;
Kaiser, Stephanie ;
Krahn, John ;
Krause, Richard ;
Kremer, Richard ;
Lepage, Raymond ;
Letendre, Elaine ;
Morin, Suzanne ;
Ooi, Daylily S. ;
Papaioaonnou, Alexandra ;
Ste-Marie, Louis-Georges .
CLINICAL BIOCHEMISTRY, 2009, 42 (10-11) :929-942
[6]   Effect of age-related chronic immobility on markers of bone turnover [J].
Chen, JS ;
Cameron, ID ;
Cumming, RG ;
Lord, SR ;
March, LM ;
Sambrook, PN ;
Simpson, JM ;
Seibel, MJ .
JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 (02) :324-331
[7]   Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis [J].
Chu, PL ;
Chao, TY ;
Lin, YF ;
Janckila, AJ ;
Yam, LT .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (05) :1052-1059
[8]   The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: A randomized controlled [J].
Clowes, JA ;
Peel, NFA ;
Eastell, R .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (03) :1117-1123
[9]   Effect of feeding on bone turnover markers and its impact on biological variability of measurements [J].
Clowes, JA ;
Hannon, RA ;
Yap, TS ;
Hoyle, NR ;
Blumsohn, A ;
Eastell, R .
BONE, 2002, 30 (06) :886-890
[10]   The direct effect of specific training and walking on bone metabolic markers in young adults with peak bone mass [J].
Csaszar, G. Gombos ;
Bajsz, V. ;
Sio, E. ;
Toth, V. Steinhausz ;
Schmidt, B. ;
Szekeres, L. ;
Kranicz, J. .
ACTA PHYSIOLOGICA HUNGARICA, 2014, 101 (02) :205-215